Back
 AiM  Vol.6 No.1 , January 2016
Screening of Anti-Infectives against Leishmania donovani
Abstract: Aim: To evaluate in vitro the effectiveness of several anti-infective agents alone and in combination against Leishmania donovani. Method: A convenient stratified sampling method was used to obtain selected anti-infective agents. For individual drug samples, Half Maximal Inhibitory Concentrations (IC50) were obtained using the broth dilution method. The IC50’s of the drugs which were active against L. donovani were used as reference values to prepare drug combinations for the modified microdilution checkerboard method. Results: Five (5) out of the fifty-six (56) drugs used showed activity (inhibition of cell growth) against L. donovani cells. They include Quinine sulphate (IC50 = 0.089 μg/ml), gentamicin (IC50 = 8.1 μg/ml), amodiaquine (IC50 = 138 μg/ml) and the two standard drugs: Amphotericin B (IC50 = 6.3 μg/ml) and Pentamidine (IC50 = 25 μg/ml). The remaining fifty-one (51) drugs did not show any inhibition within the range of concentrations used (1.25 - 160 μg/ml). The drug combinations of Pentamidine/Amodiaquine, Pentamidine/ Quinine sulphate, Pentamidine/Gentamicin, Amphotericin B/Quinine Sulphate, Amphotericin B/ Gentamicin, Amodiaquine/Quinine sulphate and Amodiaquine/Gentamicin showed synergistic effects against L. donovani whereas the Amphotericin B/Amodiaquine combination was antagonistic. Notable in the results obtained was the high effectiveness of quinine sulphate in inhibiting the growth of L. donovani. Quinine sulphate, though not indicated for leishmania treatment, was more effective than the two standard drugs and has a potential of playing a significant role in the treatment of leishmaniasis. Conclusion: This study has revealed five (5) anti-infective agents that by themselves or in combinations show activity against L. donovani. Some of the drug combinations which showed synergism should further be investigated. These results have to be confirmed by in vivo studies to define their roles in leishmaniasis treatment.
Cite this paper: Nettey, H. , Allotey-Babington, G. , Nguessan, B. , Afrane, B. , Tagoe, M. , Ababio, A. , Botchway, P. , Darko, Y. , Sasu, C. and Nyarko, A. (2016) Screening of Anti-Infectives against Leishmania donovani. Advances in Microbiology, 6, 13-22. doi: 10.4236/aim.2016.61002.
References

[1]   Banuls, A.-L., Hide, M. and Prugnolle, F. (2007) Leishmania and the Leishmaniases: A Parasite Genetic Update and Advances in Taxonomy, Epidemiology and Pathogenicity in Humans. Advances in Parasitology, 64, 1-458.
http://dx.doi.org/10.1016/S0065-308X(06)64001-3

[2]   Organization, W.H. (2000) WHO Report on Global Surveillance of Epidemic Prone Infectious Diseases, Communicable Diseases and Surveillance Response. WHO/CDS/CSR/ISR/2000, World Health Organization, Geneva.

[3]   Lukes, J., Mauricio, I.L., Schonian, G., Dujardin, J.-C., Soteriadou, K., Dedet, J.-P., et al. (2007) Evolutionary and Geographical History of the Leishmania donovani Complex with a Revision of Current Taxonomy. Proceedings of the National Academy of Sciences, 104, 9375-9380.
http://dx.doi.org/10.1073/pnas.0703678104

[4]   Andrade, B.B., Oliveira, C.I. de, Brodskyn, C.I., Barral, A. and Barral-Netto, M. (2007) Role of Sand Fly Saliva in Human and Experimental Leishmaniasis: Current Insights. Scandinavian Journal of Immunology, 66, 122-127.
http://dx.doi.org/10.1111/j.1365-3083.2007.01964.x

[5]   Titus, R.G. and Ribeiro, J.M. (1988) Salivary Gland Lysates from the Sand Fly Lutzomyia longipalpis Enhance Leishmania Infectivity. Science, 239, 1306-1308.
http://dx.doi.org/10.1126/science.3344436

[6]   Anstead, G.M., Chandrasekar, B., Zhao, W., Yang, J., Perez, L.E. and Melby, P.C. (2001) Malnutrition Alters the Innate Immune Response and Increases Early Visceralization Following Leishmania donovani Infection. Infection and Immunity, 69, 4709-4718.
http://dx.doi.org/10.1128/IAI.69.8.4709-4718.2001

[7]   Harrison, L.H., Naidu, T.G., Drew, J.S., de Alencar, J.E. and Pearson, R.D. (1986) Reciprocal Relationships between Undernutrition and the Parasitic Disease Visceral Leishmaniasis. Reviews of Infectious Diseases, 8, 447-453.
http://dx.doi.org/10.1093/clinids/8.3.447

[8]   Murray, H.W. (2001) Clinical and Experimental Advances in Treatment of Visceral Leishmaniasis. Antimicrobial Agents and Chemotherapy, 45, 2185-2197.
http://dx.doi.org/10.1128/AAC.45.8.2185-2197.2001

[9]   Rojas, R., Valderrama, L., Valderrama, M., Varona, M.X., Ouellette, M. and Saravia, N.G. (2006) Resistance to Antimony and Treatment Failure in Human Leishmania (Viannia) Infection. The Journal of Infectious Diseases, 193, 1375-1383.
http://dx.doi.org/10.1086/503371

[10]   Eucast (2000) Terminology Relating to Methods for The Determination of Susceptibility of Bacteria to Antimicrobial Agents. Eucast Definitive Document E. Def 1.2. Clinical Microbiology and Infection, 6, 503-508.

[11]   Milne, K. and Gould, I. (2012) Combination Antimicrobial Susceptibility Testing of Multidrug-Resistant Stenotrophomonas Maltophilia from Cystic Fibrosis Patients. Antimicrobial Agents and Chemotherapy, 56, 4071-4077.
http://dx.doi.org/10.1128/AAC.00072-12

[12]   Levison, M.E. and Levison, J.H. (2009) Pharmacokinetics and Pharmacodynamics of Antibacterial Agents. Infectious Disease Clinics of North America, 23, 791-815.
http://dx.doi.org/10.1016/j.idc.2009.06.008

[13]   Fitzgerald, J.B., Schoeberl, B., Nielsen, U.B. and Sorger, P.K. (2006) Systems Biology and Combination Therapy in the Quest for Clinical Efficacy. Nature Chemical Biology, 2, 458-466.
http://dx.doi.org/10.1038/nchembio817

[14]   Lehár, J., Krueger, A.S., Avery, W., Heilbut, A.M., Johansen, L.M., Price, E.R., et al. (2009) Synergistic Drug Combinations Tend to Improve Therapeutically Relevant Selectivity. Nature Biotechnology, 27, 659-666.
http://dx.doi.org/10.1038/nbt.1549

[15]   Chait, R., Craney, A. and Kishony, R. (2007) Antibiotic Interactions That Select against Resistance. Nature, 446, 668-671.
http://dx.doi.org/10.1038/nature05685

[16]   Chou, T.-C. (2006) Theoretical Basis, Experimental Design and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies. Pharmacological Reviews, 58, 621-681.
http://dx.doi.org/10.1124/pr.58.3.10

[17]   Marquez, V.E., Cranston, J.W., Ruddon, R.W., Kier, L.B. and Burckhalter, J.H. (1972) Mechanism of Action of Amodiaquine. Synthesis of Its Indoloquinoline Analog. Journal of Medicinal Chemistry, 15, 36-39.
http://dx.doi.org/10.1021/jm00271a010

[18]   Coimbra, E.S., Da Silva, A.D., Dias, R.M., Corrales, R.C., De, L.F., Bispo, M., Kaiser, C.R., et al. (2011) Amodiaquine Analogs. Synthesis and Anti-Leishmanial Activity. Mediterranean Journal of Chemistry, 1, 106-113.
http://dx.doi.org/10.13171/mjc.1.3.2011.26.09.22

[19]   Foley, M. and Tilley, L. (1997) Quinoline Antimalarials: Mechanisms of Action and Resistance. International Journal for Parasitology, 27, 231-240.
http://dx.doi.org/10.1016/S0020-7519(96)00152-X

[20]   Clark, M., Finkel, R., Rey, J. and Whalen, K. (2012) Lippincott’s Illustrated Reviews: Pharmacology. 5th Edition, Lippincott Williams and Wilkins, New York, 451.

[21]   Vij, K. (2014) Textbook of Forensic Medicine & Toxicology: Principles & Practice. Elsevier Health Sciences.

[22]   Monge-Maillo, B. and López-Vélez, R. (2014) Topical Paromomycin and Gentamicin for New World Cutaneous Leishmaniasis in Panama. The American Journal of Tropical Medicine and Hygiene, 90, 1191-1191.
http://dx.doi.org/10.4269/ajtmh.14-0040a

 
 
Top